Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • Caplin Point's sterile...

    Caplin Point's sterile injectable site in Chennai gets two USFDA observations

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-20T13:34:22+05:30  |  Updated On 20 Jun 2019 1:34 PM IST
    Caplin Points sterile injectable site in Chennai gets two USFDA observations

    New Delhi: Caplin Point Laboratories Monday said the US health regulator has made two observations after completion of inspection at its subsidiary's sterile injectable site in Tamil Nadu.


    The US Food and Drug Administration (USFDA) has completed inspection of Caplin Steriles Ltd's site at Gummidipoondi in Tamil Nadu, between June 6-14, 2019.


    At the end of this scheduled Good Manufacturing Practice (GMP) inspection, there were only two observations, Caplin Point Laboratories said in a BSE filing.


    Read Also: Caplin Point gets 2 USFDA observations for sterile injectable site in Chennai


    Caplin Point Laboratories said it believes these observations are procedural in nature and corrective and "preventive actions for these observations will be presented to the USFDA shortly".


    "The observations made did not repeat observations or related to data integrity. This was the third USFDA audit at the plant since 2016," the company added.


    Caplin Point Laboratories Chairman C C Paarthipan said: "our primary focus is to ensure the integrity and maintain transparency in our quality systems, and we're pleased with the result of yet another successful audit."


    Read Also: Caplin steriles signs license, supply agreement with Baxter for injectable portfolio


    Shares of Caplin Point Laboratories were trading 0.64 per cent lower at Rs 420 apiece on BSE.

    BSECaplincaplin sterilesChennaiGMP inspectionGood Manufacturing PracticeNew DelhiShares of Caplin Point Laboratoriessterile injectableUS Food and Drug AdministrationUS healthUSFDAUSFDA observations
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok